Top Transfection Technologies Companies

Transfection Technologies Market size was valued at USD 1.31 Billion in 2024 and is poised to grow from USD 1.44 Billion in 2025 to USD 2.95 Billion by 2033, growing at a CAGR of 9.4% during the forecast period (2026–2033).

Key vendors in the Transfection Technologies Market include Thermo Fisher Scientific Inc., Merck KGaA, Promega Corporation, Lonza Group AG, Bio-Rad Laboratories, Inc., QIAGEN N.V., MaxCyte, Inc., Mirus Bio LLC, Polyplus-transfection SA, and F. Hoffmann-La Roche Ltd.. These companies provide transfection reagents, instruments, and services for applications in gene therapy, drug discovery, vaccine development, and cell and molecular biology research, focusing on improving transfection efficiency, scalability, and cell viability.

The key driver of the Transfection Technologies Market is the increasing demand for gene and cell therapy research and development. Growing investments in biotechnology and pharmaceutical research, rising adoption of genetic engineering techniques, and expanding applications in vaccine development, drug discovery, and regenerative medicine are driving market growth.

The key market trend in the Transfection Technologies Market is the increasing adoption of non-viral transfection methods and advanced gene delivery technologies. Researchers and manufacturers are focusing on developing highly efficient, scalable, and cell-friendly transfection solutions to support emerging applications in gene editing, cell therapy, and personalized medicine.

North America accounted for the largest share in the Transfection Technologies Market due to its strong biotechnology and pharmaceutical industries, significant investments in gene and cell therapy research, and the presence of leading life sciences companies and research institutions. The region also benefits from advanced healthcare infrastructure, substantial funding for biomedical research, and rapid adoption of innovative transfection technologies.